Pulmonary embolism: what does the new AHA/ACC 2026 guide add

Area of Science:

• Cardiology
• Pulmonary Medicine
• Clinical Guidelines

Background:

• The 2026 American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for Evaluation and Management of Acute Pulmonary Embolism (PE) in Adults has been released.
• This guideline introduces updated recommendations for diagnosing and managing acute PE.

Purpose of the Study:

• To critically evaluate key sections of the new 2026 AHA/ACC Acute PE Guideline.
• To assess the clinical implications and evidence base of the guideline's recommendations.

Main Methods:

• Critical appraisal of the published 2026 AHA/ACC Acute PE Guideline.
• Review of risk classification, anticoagulant recommendations, and reperfusion therapy suggestions.

Main Results:

• The guideline introduces a more granular risk classification system for acute PE, which requires further validation.
• The guideline's preference for low-molecular-weight heparins and direct oral anticoagulants as first-line anticoagulation is supported.
• Reperfusion therapies are suggested for certain scenarios lacking strong scientific evidence.

Conclusions:

• The new risk stratification in the AHA/ACC Acute PE Guideline needs validation.
• Current evidence supports the recommended anticoagulants for most acute PE patients.
• Further clinical trials are necessary to establish definitive indications for suggested reperfusion therapies in acute PE management.